• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc (Amendment)

    2/14/24 5:04:58 PM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email
    SC 13G/A 1 adaptimmune_13ga1.htm SC 13G/A
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    ADAPTIMMUNE THERAPEUTICS PLC

     

    (Name of Issuer)

    American Depositary Shares

     

    (Title of Class of Securities)

    00653A107

     

    (CUSIP Number)

    Long Focus Capital Management LLC
    207 Calle Del Parque
    A&M Tower, 8th Floor
    San Juan, PR 00912
    (787) 333-0240

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    o  Rule 13d-1(c)
    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
             
    CUSIP No. 00653A107   13G   Page 2 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    LONG FOCUS CAPITAL MANAGEMENT, LLC
    46-2772035
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE, USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    12,086,915

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    12,086,915

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    12,086,915 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.3%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
     
     
             
    CUSIP No. 00653A107   13G   Page 3 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    LONG FOCUS CAPITAL MASTER, LTD.
    46-3004723
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    7,090,676

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    7,090,676

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,090,676 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.1%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    FI
       
     
     
             
    CUSIP No. 00653A107   13G   Page 4 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    CONDAGUA, LLC
    47-3021161
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE, USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    4,996,239

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    4,996,239

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,996,239 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    OO
       
     
     
             
    CUSIP No. 00653A107   13G   Page 5 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    JOHN B. HELMERS
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    12,086,915

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    12,086,915

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    12,086,915 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.3%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
     
     
             
    CUSIP No. 00653A107   13G   Page 6 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    A. GLENN HELMERS
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    4,996,239

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    4,996,239

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,996,239 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
     
     
             
    CUSIP No. 00653A107   13G   Page 7 of 10 Pages
             

    Item 1.

     

      (a) Name of Issuer
    ADAPTIMMUNE THERAPEUTICS PLC
         
      (b)

    Address of Issuer’s Principal Executive Offices
    60 Jubilee Avenue, Milton Park
    Abingdon, Oxfordshire OX14 4RX
    United Kingdom

         

    Item 2.

     

      (a)

    Name of Person Filing
    LONG FOCUS CAPITAL MANAGEMENT, LLC

    LONG FOCUS CAPITAL MASTER, LTD.

    CONDAGUA, LLC
    JOHN B. HELMERS
    A. GLENN HELMERS

         
      (b)

    Address of the Principal Office or, if none, residence
    207 CALLE DEL PARQUE

    A&M TOWER, 8TH FLOOR

    SAN JUAN, PR 00912

         
      (c) Citizenship
    Long Focus Capital Management, LLC, a Delaware single member limited liability company;
    Long Focus Capital Master, LTD., a Cayman Islands limited company;
    Condagua, LLC, a Delaware single member limited liability company;
    John B. Helmers, a United States citizen; and
    A. Glenn Helmers, a United States citizen.
         
      (d) Title of Class of Securities
    American Depositary Shares
         
      (e) CUSIP Number
    00653A107

     
     
             
    CUSIP No. 00653A107   13G   Page 8 of 10 Pages
             

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

     

    Long Focus Capital Management, LLC, John B. Helmers, and A. Glenn Helmers directly own no American Depositary Shares. A. Glenn Helmers controls Condagua, LLC. Pursuant to an investment management agreement, Long Focus Capital Management, LLC maintains investment and voting power with respect to the American Depositary Shares held by Long Focus Capital Master, Ltd. John B. Helmers controls Long Focus Capital Management, LLC, and maintains investment and voting power with respect to the American Depositary Shares held by Condagua, LLC.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     
     
             
    CUSIP No. 00653A107   13G   Page 9 of 10 Pages
             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     o.

    Instruction. Dissolution of a group requires a response to this item.

    NOT APPLICABLE

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    NOT APPLICABLE

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    NOT APPLICABLE

    Item 8.  Identification and Classification of Members of the Group.

    NOT APPLICABLE

    Item 9.  Notice of Dissolution of Group.

    NOT APPLICABLE

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
     
     
             
    CUSIP No. 00653A107   13G   Page 10 of 10 Pages
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      LONG FOCUS CAPITAL MANAGEMENT, LLC
       
      /s/ John B. Helmers
      John B. Helmers/Managing Member
       
      LONG FOCUS CAPITAL MASTER, LTD.
      BY: LONG FOCUS CAPITAL MANAGEMENT, LLC
    ITS: INVESTMENT ADVISER
       
      /s/ John B. Helmers
      John B. Helmers/Managing Member
       
      CONDAGUA, LLC
       
      /s/ A. Glenn Helmers
      A. Glenn Helmers/Managing Member
       
      JOHN B. HELMERS
       
      /s/ John B. Helmers
      John B. Helmers
       
      A. GLENN HELMERS
       
      /s/ A. Glenn Helmers
      A. Glenn Helmers
     
    Get the next $ADAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAP

    DatePrice TargetRatingAnalyst
    7/30/2024$4.00Buy
    H.C. Wainwright
    5/30/2024$3.15Sector Outperform
    Scotiabank
    3/24/2023$3.60Buy
    Bryan Garnier
    1/3/2023$5.00Neutral → Buy
    Guggenheim
    11/9/2022$9.00Neutral → Buy
    Mizuho
    9/22/2021$6.00 → $7.00Equal-Weight
    Wells Fargo
    9/13/2021$6.00 → $7.00Market Perform
    SVB Leerink
    9/7/2021$5.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:35:34 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:34:48 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Patient Supply Officer Lunger John

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:33:25 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

      7/30/24 6:31:41 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

      Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

      5/30/24 7:25:43 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bryan Garnier initiated coverage on Adaptimmune Therapeutics with a new price target

      Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60

      3/24/23 9:09:04 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      11/13/24 9:04:55 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13D/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      4/2/24 8:38:07 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      3/26/24 11:59:28 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    SEC Filings

    See more
    • Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      5/1/25 4:15:32 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adaptimmune Therapeutics plc

      DEF 14A - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/25/25 8:02:51 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Adaptimmune Therapeutics plc

      S-3 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/18/25 4:32:27 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Financials

    Live finance-specific insights

    See more
    • Adaptimmune Reports Q3 2024 Financial and Business Updates

      Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million

      11/13/24 4:05:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Reports Q2 2024 Financial and Business Updates

      Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod

      8/12/24 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

      Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0

      8/1/24 8:20:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care